List of Daybue drug patents

Daybue is owned by Acadia Pharms Inc.

Daybue contains Trofinetide.

Daybue has a total of 2 drug patents out of which 0 drug patents have expired.

Daybue was authorised for market use on 10 March, 2023.

Daybue is available in solution;oral dosage forms.

Daybue can be used as treatment of rett syndrome or a symptom thereof.

Drug patent challenges can be filed against Daybue from 2027-03-11.

The generics of Daybue are possible to be released after 03 August, 2040.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11370755 ACADIA PHARMS INC Compositions of trofinetide
Aug, 2040

(17 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9212204 ACADIA PHARMS INC Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid
Jan, 2032

(8 years from now)

Do you want to check out DAYBUE patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 10, 2030
New Chemical Entity Exclusivity (NCE) Mar 10, 2028

Drugs and Companies using TROFINETIDE ingredient

NCE-1 date: 2027-03-11

Market Authorisation Date: 10 March, 2023

Treatment: Treatment of rett syndrome or a symptom thereof


More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in